Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 4Glioma 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Temozolomide 156Bevacizumab 69Radiotherapy 61Magnetic Resonance Spectroscopy 59Irinotecan 31Surgical Procedures, Operative 23Radiation 23Carboplatin 23Specimen Handling 20Carmustine 20Nivolumab 19Biopsy 17Lomustine 16Aminolevulinic Acid 15Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12pembrolizumab 12Radiosurgery 12Erlotinib Hydrochloride 12fluorodopa F 18 11Topotecan 11Everolimus 11Blood Specimen Collection 11X-Rays 10IL13-PE38 10dabrafenib 9Etoposide 9ribociclib 8poly ICLC 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Glioma × azeliragon × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

City of Hope Medical Center

Phase 1 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡